Quarterly report · Q2
2784.TEDINET S100S6JK
Period2023-04-01 → 2023-09-30
Filed2023-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.43T | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥2.70T | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.33T | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥16.0bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥10.2bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥17.3bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥32.8bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥11.5bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥17.4bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥11.1bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥11.8bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥25.8bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥7.0bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥11.9bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥7.0bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥1.43T | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥1.34T | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.33T | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥960.7bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥851.5bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥465.6bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥488.3bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥481.9bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥186.2bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥160.1bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥184.8bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥158.8bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥168.2bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥179.1bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥63.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥13.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥10.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥8.7bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥20.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥15.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥29.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥12.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥6.4bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥60.29 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥40.57 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥127.42 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥34.6 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥24.1 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 32.6% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.4% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.1% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥16.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥16.9bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | ¥269m |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥1.27T |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥1.26T |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥8.9bn |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥13.8bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥26.0bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥18.3bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥7.7bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥186m |
| jpcrp040300-q2r_E02962-000Medical Related Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥18.2bn |
| jpcrp040300-q2r_E02962-000Medical Related Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥18.2bn |
| jpcrp040300-q2r_E02962-000Medical Related Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥279m |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥133.3bn |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥133.1bn |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥275m |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥1.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥1.44T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥1.43T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥16.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥15.7bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥15.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥15.2bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | ¥245m |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥1.18T |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥1.17T |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥8.3bn |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥8.0bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥23.6bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥17.0bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥6.6bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥842m |
| jpcrp040300-q2r_E02962-000Medical Related Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥17.9bn |
| jpcrp040300-q2r_E02962-000Medical Related Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥17.9bn |
| jpcrp040300-q2r_E02962-000Medical Related Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥14m |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥124.1bn |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥123.8bn |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥305m |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥1.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥1.35T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥1.33T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥15.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥10.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 538
| Item | Context | Value | Unit |
|---|---|---|---|
| Provision for share based remuneration ncl | CurrentQuarterInstant | 138000000 | JPY |
| Provision for share based remuneration for directors and other officers ncl | Prior1YearInstant | 90000000 | JPY |
| Provision for share based remuneration for directors and other officers ncl | CurrentQuarterInstant | 181000000 | JPY |
| Net defined benefit liability | Prior1YearInstant | 8363000000 | JPY |
| Net defined benefit liability | CurrentQuarterInstant | 7896000000 | JPY |
| Other ncl | Prior1YearInstant | 17257000000 | JPY |
| Other ncl | CurrentQuarterInstant | 19147000000 | JPY |
| Noncurrent liabilities | Prior1YearInstant | 25784000000 | JPY |
| Noncurrent liabilities | CurrentQuarterInstant | 27363000000 | JPY |
| Liabilities | Prior1YearInstant | 851517000000 | JPY |
| Liabilities | CurrentQuarterInstant | 960663000000 | JPY |
| Capital stock | Prior1YearInstant | 18454000000 | JPY |
| Capital stock | CurrentQuarterInstant | 18454000000 | JPY |
| Capital surplus | Prior1YearInstant | 57720000000 | JPY |
| Capital surplus | CurrentQuarterInstant | 57720000000 | JPY |
| Retained earnings | Prior1YearInstant | 366649000000 | JPY |
| Retained earnings | CurrentQuarterInstant | 373143000000 | JPY |
| Treasury stock | Prior1YearInstant | -686000000 | JPY |
| Treasury stock | CurrentQuarterInstant | -35430000000 | JPY |
| Shareholders equity | Prior1YearInstant | 442137000000 | JPY |
| Shareholders equity | CurrentQuarterInstant | 413887000000 | JPY |
| Valuation difference on available for sale securities | Prior1YearInstant | 47135000000 | JPY |
| Valuation difference on available for sale securities | CurrentQuarterInstant | 52718000000 | JPY |
| Deferred gains or losses on hedges | Prior1YearInstant | -0 | JPY |
| Deferred gains or losses on hedges | CurrentQuarterInstant | － | JPY |
| Revaluation reserve for land | Prior1YearInstant | -3346000000 | JPY |
| Revaluation reserve for land | CurrentQuarterInstant | -3346000000 | JPY |
| Foreign currency translation adjustment | Prior1YearInstant | 269000000 | JPY |
| Foreign currency translation adjustment | CurrentQuarterInstant | 333000000 | JPY |
| Remeasurements of defined benefit plans | Prior1YearInstant | 1895000000 | JPY |
| Remeasurements of defined benefit plans | CurrentQuarterInstant | 1677000000 | JPY |
| Valuation and translation adjustments | Prior1YearInstant | 45953000000 | JPY |
| Valuation and translation adjustments | CurrentQuarterInstant | 51382000000 | JPY |
| Non controlling interests | Prior1YearInstant | 244000000 | JPY |
| Non controlling interests | CurrentQuarterInstant | 283000000 | JPY |
| Net assets | Prior1YearInstant | 488335000000 | JPY |
| Net assets | CurrentQuarterInstant | 465552000000 | JPY |
| Liabilities and net assets | Prior1YearInstant | 1339852000000 | JPY |
| Liabilities and net assets | CurrentQuarterInstant | 1426216000000 | JPY |
| Net sales | Prior1YTDDuration | 1332419000000 | JPY |
| Net sales | CurrentYTDDuration | 1427856000000 | JPY |
| Cost of sales | Prior1YTDDuration | 1241379000000 | JPY |
| Cost of sales | CurrentYTDDuration | 1328630000000 | JPY |
| Gross profit | Prior1YTDDuration | 91039000000 | JPY |
| Gross profit | CurrentYTDDuration | 99226000000 | JPY |
| Selling general and administrative expenses | Prior1YTDDuration | 80812000000 | JPY |
| Selling general and administrative expenses | CurrentYTDDuration | 83228000000 | JPY |
| Operating income | Prior1YTDDuration | 10227000000 | JPY |
| Operating income | CurrentYTDDuration | 15998000000 | JPY |
| Interest income noi | Prior1YTDDuration | 30000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |